These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 2056136)
21. Relative efficacy of parenteral haloperidol and thiothixene for the emergency treatment of acutely excited and agitated patients. Stotsky BA Dis Nerv Syst; 1977 Dec; 38(12):967-73. PubMed ID: 338270 [TBL] [Abstract][Full Text] [Related]
22. A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis. Oosthuizen P; Emsley R; Jadri Turner H; Keyter N Int J Neuropsychopharmacol; 2004 Jun; 7(2):125-31. PubMed ID: 15003147 [TBL] [Abstract][Full Text] [Related]
23. Haloperidol decanoate pharmacokinetics in red blood cells and plasma. Dysken MW; Kim SW; Vatassery G; Johnson SB; Skare S; Holden L; Thomsyck L J Clin Psychopharmacol; 1992 Apr; 12(2):128-32. PubMed ID: 1573034 [TBL] [Abstract][Full Text] [Related]
24. Choreiform movements induced by anticholinergic therapy. West RR; Newgreen DB Med J Aust; 1979 Jul; 2(2):87-8. PubMed ID: 492035 [No Abstract] [Full Text] [Related]
26. Psychotic symptoms preceding ocular deviation in a patient with tardive oculogyric crises. Sachdev P; Tang WM Aust N Z J Psychiatry; 1992 Dec; 26(4):666-70. PubMed ID: 1362053 [TBL] [Abstract][Full Text] [Related]
27. Comparative side effects of imipramine, benztropine, or their combination in patients receiving fluphenazine decanoate. Siris SG; Rifkin A; Reardon GT; November M Am J Psychiatry; 1983 Aug; 140(8):1069-71. PubMed ID: 6346910 [TBL] [Abstract][Full Text] [Related]
28. Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures. Gardos G; Cole JO; Rapkin RM; LaBrie RA; Baquelod E; Moore P; Sovner R; Doyle J Arch Gen Psychiatry; 1984 Nov; 41(11):1030-5. PubMed ID: 6149737 [TBL] [Abstract][Full Text] [Related]
29. A study of the need for anticholinergic medication in patients treated with long-term antipsychotics. Caradoc-Davies G; Menkes DB; Clarkson HO; Mullen PE Aust N Z J Psychiatry; 1986 Jun; 20(2):225-32. PubMed ID: 2876700 [TBL] [Abstract][Full Text] [Related]
30. Dosage of haloperidol for mania. Rifkin A; Doddi S; Karajgi B; Borenstein M; Munne R Br J Psychiatry; 1994 Jul; 165(1):113-6. PubMed ID: 7953013 [TBL] [Abstract][Full Text] [Related]
31. A two-phase, double-blind randomized study of three haloperidol plasma levels for acute psychosis with reassignment of initial non-responders. Janicak PG; Javaid JI; Sharma RP; Leach A; Dowd S; Davis JM Acta Psychiatr Scand; 1997 Apr; 95(4):343-50. PubMed ID: 9150830 [TBL] [Abstract][Full Text] [Related]
32. Efficacy of maintenance use of anticholinergic agents. Double DB; Warren GC; Evans M; Rowlands RP Acta Psychiatr Scand; 1993 Nov; 88(5):381-4. PubMed ID: 7905226 [TBL] [Abstract][Full Text] [Related]
33. Acute dystonia during fixed-dose neuroleptic treatment. Singh H; Levinson DF; Simpson GM; Lo ES; Friedman E J Clin Psychopharmacol; 1990 Dec; 10(6):389-96. PubMed ID: 2286708 [TBL] [Abstract][Full Text] [Related]
34. Optimal haloperidol dosage in first-episode psychosis. Zhang-Wong J; Zipursky RB; Beiser M; Bean G Can J Psychiatry; 1999 Mar; 44(2):164-7. PubMed ID: 10097837 [TBL] [Abstract][Full Text] [Related]
35. A comparative study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benztropine in schizophrenia. Theoretical implications for potency differences among neuroleptics. Singh MM; Kay SR Psychopharmacologia; 1975 Aug; 43(2):103-13. PubMed ID: 1103205 [TBL] [Abstract][Full Text] [Related]